Using artificial cells to enhance cancer immunotherapy
Mechanically active artificial antigen presenting cells for cancer immunotherapy
This study is looking at how specially designed cells can help boost the immune system's T cells to fight cancer better, and it aims to find out how the forces between these cells affect their ability to work, which could lead to improved cancer treatments for patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Harvard University NIH-funded |
| Lab location | 1 site (Cambridge, United States) |
| Project ID | NIH-11017049 on NIH RePORTER |
What this research studies
This research investigates how artificially designed antigen-presenting cells can improve the activation of T cells in the immune response against cancer. By measuring the mechanical forces involved when T cells interact with these artificial cells, the study aims to understand how these forces influence T cell activation and specificity. The approach includes developing innovative methods to quantify these forces and testing how different drugs can affect cell mechanics. Patients may benefit from advancements in immunotherapy that could lead to more effective cancer treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with cancer who may benefit from enhanced immunotherapy treatments.
Not a fit: Patients who do not have cancer or those whose cancer is not amenable to immunotherapy may not receive benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer immunotherapies that harness the body's immune system to fight tumors.
How similar studies have performed: Other research has shown promising results in enhancing T cell responses through mechanical and biochemical modulation, suggesting potential for success in this novel approach.
Where this research is happening
Cambridge, United States
- Harvard University — Cambridge, United States (Active)
Researchers
- Principal investigator: Hu, Yuesong — Harvard University
- Study coordinator: Hu, Yuesong
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.